
    
      Samfenet is a biosimilar of trastuzumab and received marketing approval based on the results
      of efficacy equivalence to trastuzumab. This study is a phase 2 study to investigate the
      efficacy of Samfenet in combination with cytotoxic agents in patients with HER2-positive
      solid tumors.

      A total of 42 patients will be enrolled. Treatment will be continues until disease
      progression, unacceptable toxicity or patient withdrawal. Tumor evaluation will be performed
      at every 8 weeks during treatment, and then at every 12 weeks thereafter end of study.
    
  